|
1
|
Ploeg M, Aben KK and Kiemeney LA: The
present and future burden of urinary bladder cancer in the world.
World J Urol. 279:289–293. 2009. View Article : Google Scholar
|
|
2
|
Jacobs BL, Lee CT and Montie JE: Bladder
cancer in 2010: how far have we come? CA Cancer J Clin. 60:244–272.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kumar V, Abbas AK and Fausto N: Pathologic
Basis of Disease. 8th edition. Saunders Elsevier; Philadelephia,
PA: pp. 976–980. 2010
|
|
4
|
Shariat SF, Karakiewicz PI, Palapattu GS,
et al: Outcomes of radical cystectomy for transitional cell
carcinoma of the bladder: a contemporary series from the Bladder
Cancer Research Consortium. J Urol. 176:2414–2422. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Morgan TM and Clark PE: Bladder cancer.
Curr Opin Oncol. 22:242–249. 2010. View Article : Google Scholar
|
|
6
|
Patra SK: Dissecting lipid raft
facilitated cell signaling pathways in cancer. Biochim Biophys
Acta. 1785:182–206. 2008.PubMed/NCBI
|
|
7
|
Patra SK and Bettuzzi S: Epigenetic
DNA-methylation regulation of genes coding for lipid
raft-associated components: A role for raft proteins in cell
transformation and cancer progression (Review). Oncol Rep.
17:1279–1290. 2007.PubMed/NCBI
|
|
8
|
Lingwood D and Simons K: Lipid rafts as a
membrane-organizing principle. Science. 327:46–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jacobson K, Mouritsen OG and Anderson RG:
Lipid rafts: at a crossroad between cell biology and physics. Nat
Cell Biol. 9:7–14. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Simons K and Toomre D: Lipid rafts and
signal transduction. Nat Rev Mol Cell Biol. 1:31–39. 2000.
View Article : Google Scholar
|
|
11
|
Mollinedo F, de la Iglesia-Vicente J,
Gajate C, et al: Lipid raft-targeted therapy in multiple myeloma.
Oncogene. 29:3748–3757. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hitosugi T, Sato M, Sasaki K and Umezawa
Y: Lipid raft specific knockdown of SRC family kinase activity
inhibits cell adhesion and cell cycle progression of breast cancer
cells. Cancer Res. 67:8139–8148. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lang DM, Lommel S, Jung M, Ankerhold R and
Petrausch B: Identification of reggie-1 and reggie-2 as
plasmamembrane-associated proteins which cocluster with activated
GPI-anchored cell adhesion molecules in non-caveolar micropatches
in neurons. J Neurobiol. 37:502–523. 1998. View Article : Google Scholar
|
|
14
|
Stuermer CA, Lang DM, Kirsch F, Wiechers
M, Deininger SO and Plattner H: Glycosylphosphatidyl
inositol-anchored proteins and fyn kinase assemble in noncaveolar
plasma membrane microdomains defined by reggie-1 and -2. Mol Biol
Cell. 12:3031–3045. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schulte T, Paschke KA, Laessing U,
Lottspeich F and Stuermer CA: Reggie-1 and reggie-2, two cell
surface proteins expressed by retinal ganglion cells during axon
regeneration. Development. 124:577–587. 1997.PubMed/NCBI
|
|
16
|
Banning A, Tomasovic A and Tikkanen R:
Functional aspects of membrane association of reggie/flotillin
proteins. Curr Protein Pept Sci. 12:725–735. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Riento K, Frick M, Schafer I and Nichols
BJ: Endocytosis of flotillin-1 and flotillin-2 is regulated by Fyn
kinase. J Cell Sci. 122:912–918. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Baumann CA, Ribon V, Kanzaki M, et al: CAP
defines a second signaling pathway required for insulin-stimulated
glucose transport. Nature. 407:202–207. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin C, Wu Z, Lin X, et al: Knockdown of
FLOT1 impairs cell proliferation and tumorigenicity in breast
cancer through upregulation of FOXO3a. Clin Cancer Res.
17:3089–3099. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hazarika P, McCarty MF, Prieto VG, et al:
Up-regulation of Flotillin-2 is associated with melanoma
progression and modulates expression of the thrombin receptor
protease activated receptor 1. Cancer Res. 64:7361–7369. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thorn CC, Freeman TC, Scott N, Guillou PJ
and Jayne DG: Laser microdissection expression profiling of
marginal edges of colorectal tumours reveals evidence of increased
lactate metabolism in the aggressive phenotype. Gut. 58:404–412.
2009. View Article : Google Scholar
|
|
22
|
Song L, Gong H, Lin C, et al: Flotillin-1
promotes tumor necrosis factor-α receptor signaling and activation
of NF-κB in esophageal squamous cell carcinoma cells.
Gastroenterology. 143:995–1005.e12. 2012.PubMed/NCBI
|
|
23
|
Santamaria A, Castellanos E, Gomez V, et
al: PTOV1 enables the nuclear translocation and mitogenic activity
of flotillin-1, a major protein of lipid rafts. Mol Cell Biol.
25:1900–1911. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gomez V, Sese M, Santamara A, et al:
Regulation of aurora B kinase by the lipid raft protein
flotillin-1. J Biol Chem. 285:20683–20690. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sternlicht MD and Werb Z: How matrix
metalloproteinases regulate cell behavior. Annu Res Cell Dev Biol.
17:465–516. 2001.
|
|
26
|
Lerner SP: Bladder cancer clinical trials.
Urol Oncol. 23:275–279. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mitsumori K, Tsuchiya N, Habuchi T, et al:
Early and large-dose intravesical instillation of epirubicin to
prevent superficial bladder carcinoma recurrence after
transurethral resection. BJU Int. 94:317–321. 2004. View Article : Google Scholar
|
|
28
|
Brausi M, Collette L and Kurth K:
Variability in the recurrence rate at first follow up cystoscopy
after TUR in stage Ta T1 transitional cell carcinoma of the
bladder: a combined analysis of seven EORTC studies. Eur Urol.
41:523–531. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sylvester RJ, Oosterlinck W and Van der
Meijden AP: A single immediate postoperative instillation of
chemotherapy decreases the risk of recurrence in patients with
stage TaT1 bladder cancer: a meta analysis of published results of
randomized clinical trials. J Urol. 171:2186–2190. 2004. View Article : Google Scholar
|
|
30
|
Pust S, Klokk TI, Musa N, et al:
Flotillins as regulators of ErbB2 levels in breast cancer.
Oncogene. 32:3443–3451. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang SH, Wang CJ, Shi L, et al: High
expression of FLOT1 is associated with progression and poor
prognosis in hepatocellular carcinoma. PLoS One. 8:e647092013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ajili F, Darouiche A, Chebil M and
Boubaker S: The efficiency of the EORTC scoring system for the
prediction of recurrence and progression of non-muscle-invasive
bladder cancer treated by bacillus calmette-guerin immunotherapy.
Ultrastruct Pathol. 37:249–253. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu T, Zhu Z, Zhang X, et al: Predicting
recurrence and progression in chinese patients with
nonmuscle-invasive bladder cancer using EORTC and CUETO scoring
models. Urology. 82:387–393. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mares J, Szakacsova M, Soukup V, et al:
Prediction of recurrence in low and intermediate risk non-muscle
invasive bladder cancer by real-time quantitative PCR analysis:
cDNA microarray results. Neoplasma. 60:295–301. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hafner C, Knuechel R, Zanardo L, et al:
Evidence for oligoclonality and tumor spread by intraluminal
seeding in multifocal urothelial carcinomas of the upper and lower
urinary tract. Oncogene. 20:4910–4915. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shang D, Liu Y, Yang P, et al:
TGFBI-promoted adhesion, migration and invasion of human renal cell
carcinoma depends on inactivation of von Hippel-Lindau tumor
suppressor. Urology. 79:966e1–966e7. 2012. View Article : Google Scholar : PubMed/NCBI
|
